Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Long-Term Safety of CLBR001, A Lentiviral Based Chimeric Antigen Receptor, In Patients With B-Cell Malignancies Previously Administered CLBR001

NCT04488354 is registered in ClinicalTrials.gov with Calibr, a division of Scripps Research as lead sponsor.

NCT NCT04488354
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04488354 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Long-Term Safety of CLBR001, A Lentiviral Based Chimeric Antigen Receptor, In Patients With B-Cell Malignancies Previously Administered CLBR001
Lead sponsor
Calibr, a division of Scripps Research
Phase
Phase 1
Overall status
Completed
Start date
January 21, 2021
Completion date
October 6, 2025
Enrollment
16 (actual)
Sites
8

Conditions

As the registry lists them; a condition with its own page is linked.

burkitt lymphoma, chronic lymphocytic leukemia (cll), diffuse large b-cell lymphoma (dlbcl), follicular lymphoma (fl), lymphoplasmacytic lymphoma, mantle cell lymphoma (mcl), marginal zone lymphoma (mzl), primary mediastinal large b cell lymphoma, relapsed/refractory b-cell lymphomas, small lymphocytic lymphoma (sll), transformed follicular lymphoma, waldenstrom macroglobulinemia